Drug Company Helps Shift Treatment Focus

March 14, 2012 | Seattle Genetics’ first product, Adcetris, was approved by FDA in August. The drug targets a receptor in Hodgkin’s disease and anaplastic large cell lymphoma. The drug works, but the target market is small. So Seattle Genetics is launching a study to find other cancers with the same receptor. The company is calling for tumor biopsies from 2,500 patients looking for the receptor their drug targets. The study could mark a shift from treatment focused on cancer type to treatment focused on specific markers. Xconomy